Better COVID Stock: Moderna vs. Pfizer
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were the first to win U.S. Emergency Use Authorization (EUA) for their respective COVID-19 vaccines. This success has made Moderna a huge winner for shareholders, with the stock skyrocketing more than 570% over the last 12 months. It's been a different story for Pfizer, though, with the big drugmaker's shares rising only around 15% during the same period -- well below the return of the S&P 500 index.
But which of these two COVID-focused stocks is the better pick now? Here's how Pfizer and Moderna stack up against each other.
Image source: Getty Images.
Source Fool.com
